The DOI matches its Crossref record; 129 of the 129 references it cites were found in a registry or an index.
Diffuse large B-cell lymphoma—treatment approaches in the molecular era
Open accessAbstract
Diffuse large B-cell lymphoma (DLBCL) is an aggressive B-cell non-Hodgkin lymphoma that affects patients of all ages with a wide range of clinical presentations. Although DLBCL is curable even in advanced stages, up to one-third of patients will not achieve cure with initial therapy. In the modern era of rituximab-based therapy as the first-line treatment, the prognoses of patients who require salvage therapy are poor and most will eventually succumb to their disease. Insight into the complex molecular circuitry of DLBCL reveals a diverse range of somatic mutations and aberrant intracellular signalling pathways that characterize distinct molecular subsets of the disease. The next major breakthrough in DLBCL therapy during this 'molecular era' of disease definition will be the identification of combinations of novel agents that target the oncogenic drivers of these subsets. Well-conducted clinical trials, with translational molecular investigations, will be essential to achieve the goal of precision medicine and expand the number of patients with DLBCL who achieve a cure.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Dasmahapatra, G. P., Lembersky, D., Kramer, L. B., Fisher, R. I., Friedberg, J. W., Dent, P., & Grant, S. (2010) · Blood · doi:10.1182/blood-2009-12-257261 · Cited by 115
RetractedSiegel, R., Naishadham, D., & Jemal, A. (2013) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.21166 · Cited by 11,825
Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling
Alizadeh, A. A., Eisen, M. B., Davis, R. E., Ma, C., Lossos, I. S., Rosenwald, A., Boldrick, J. C., Sabet, H., Tran, T., Yu, X., et al. (2000) · Nature · doi:10.1038/35000501 · Cited by 9,925
Self-citationShrestha, S., & Offer, S. M. (2016) · Medical Epigenetics · doi:10.1159/000444713 · Cited by 8,914
Coiffier, B., Lepage, E., Brière, J., Herbrecht, R., Tilly, H., Bouabdallah, R., Morel, P., Van Den Neste, E., Salles, G., Gaulard, P., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa011795 · Cited by 5,574
PD-1 and Its Ligands in Tolerance and Immunity
Keir, M. E., Butte, M. J., Freeman, G. J., & Sharpe, A. H. (2008) · Annual Review of Immunology · doi:10.1146/annurev.immunol.26.021607.090331 · Cited by 5,378
A Predictive Model for Aggressive Non-Hodgkin's Lymphoma
(1993) · New England Journal of Medicine · doi:10.1056/nejm199309303291402 · Cited by 4,949
Rosenwald, A., Wright, G., Chan, W. C., Connors, J. M., Campo, E., Fisher, R. I., Gascoyne, R. D., Muller-Hermelink, H. K., Smeland, E. B., Giltnane, J. M., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa012914 · Cited by 3,829
Self-citationIwai, Y., Ishida, M., Tanaka, Y., Okazaki, T., Honjo, T., & Minato, N. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.192461099 · Cited by 3,203
ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets
Souers, A. J., Leverson, J. D., Boghaert, E. R., Ackler, S. L., Catron, N. D., Chen, J., Dayton, B. D., Ding, H., Enschede, S. H., Fairbrother, W. J., et al. (2013) · Nature Medicine · doi:10.1038/nm.3048 · Cited by 3,058
BET Bromodomain Inhibition as a Therapeutic Strategy to Target c-Myc
Delmore, J. E., Issa, G. C., Lemieux, M. E., Rahl, P. B., Shi, J., Jacobs, H. M., Kastritis, E., Gilpatrick, T., Paranal, R. M., Qi, J., et al. (2011) · Cell · doi:10.1016/j.cell.2011.08.017 · Cited by 2,813
Appio, L., Landoni, C., La Targia, M., Bertolli, V., Chiarucci, M., Crovetti, G., Vassenna, E., Serio, G., & Bregni, M. (2017) · Chemotherapy · doi:10.1159/000458147 · Cited by 2,327
Fisher, R. I., Gaynor, E. R., Dahlberg, S., Oken, M. M., Grogan, T. M., Mize, E. M., Glick, J. H., Coltman, C. A., & Miller, T. P. (1993) · New England Journal of Medicine · doi:10.1056/nejm199304083281404 · Cited by 2,149
Pfreundschuh, M., Trümper, L., Österborg, A., Pettengell, R., Trneny, M., Imrie, K., Ma, D., Gill, D., Walewski, J., Zinzani, P.-L., et al. (2006) · The Lancet Oncology · doi:10.1016/s1470-2045(06)70664-7 · Cited by 2,076
Stromal Gene Signatures in Large-B-Cell Lymphomas
Lenz, G., Wright, G., Dave, S. S., Xiao, W., Powell, J., Zhao, H., Xu, W., Tan, B., Goldschmidt, N., Iqbal, J., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802885 · Cited by 1,808
Self-citationEZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations
McCabe, M. T., Ott, H. M., Ganji, G., Korenchuk, S., Thompson, C., Van Aller, G. S., Liu, Y., Graves, A. P., III, A. D. P., Diaz, E., et al. (2012) · Nature · doi:10.1038/nature11606 · Cited by 1,786
Principles of cancer therapy: oncogene and non-oncogene addiction
Luo, J., Solimini, N. L., & Elledge, S. J. (2009) · Cell · doi:10.1016/j.cell.2009.02.024 · Cited by 1,765
Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma
Davis, R. E., Ngo, V. N., Lenz, G., Tolar, P., Young, R. M., Romesser, P. B., Kohlhammer, H., Lamy, L., Zhao, H., Yang, Y., et al. (2010) · Nature · doi:10.1038/nature08638 · Cited by 1,643
Self-citationGisselbrecht, C., Glass, B., Mounier, N., Singh Gill, D., Linch, D. C., Trneny, M., Bosly, A., Ketterer, N., Shpilberg, O., Hagberg, H., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.1618 · Cited by 1,625
Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma
Morin, R. D., Mendez-Lago, M., Mungall, A. J., Goya, R., Mungall, K. L., Corbett, R. D., Johnson, N. A., Severson, T. M., Chiu, R., Field, M., et al. (2011) · Nature · doi:10.1038/nature10351 · Cited by 1,614
Honigberg, L. A., Smith, A. M., Sirisawad, M., Verner, E., Loury, D., Chang, B., Li, S., Pan, Z., Thamm, D. H., Miller, R. A., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1004594107 · Cited by 1,561
Coiffier, B., Thieblemont, C., Van Den Neste, E., Lepeu, G., Plantier, I., Castaigne, S., Lefort, S., Marit, G., Macro, M., Sebban, C., et al. (2010) · Blood · doi:10.1182/blood-2010-03-276246 · Cited by 1,540
Morin, R. D., Johnson, N. A., Severson, T. M., Mungall, A. J., An, J., Goya, R., Paul, J. E., Boyle, M., Woolcock, B. W., Kuchenbauer, F., et al. (2010) · Nature Genetics · doi:10.1038/ng.518 · Cited by 1,521
Oncogenically active MYD88 mutations in human lymphoma
Ngo, V. N., Young, R. M., Schmitz, R., Jhavar, S., Xiao, W., Lim, K.-H., Kohlhammer, H., Xu, W., Yang, Y., Zhao, H., et al. (2011) · Nature · doi:10.1038/nature09671 · Cited by 1,512
Self-citationThe Concept of Synthetic Lethality in the Context of Anticancer Therapy
Kaelin, W. G. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1691 · Cited by 1,379
Green, M. R., Monti, S., Rodig, S. J., Juszczynski, P., Currie, T., O'Donnell, E., Chapuy, B., Takeyama, K., Neuberg, D., Golub, T. R., et al. (2010) · Blood · doi:10.1182/blood-2010-05-282780 · Cited by 1,305
Advani, R. H., Buggy, J. J., Sharman, J. P., Smith, S. M., Boyd, T. E., Grant, B., Kolibaba, K. S., Furman, R. R., Rodriguez, S., Chang, B. Y., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.42.7906 · Cited by 1,128
Rosenwald, A., Wright, G., Leroy, K., Yu, X., Gaulard, P., Gascoyne, R. D., Chan, W. C., Zhao, T., Haioun, C., Greiner, T. C., et al. (2003) · The Journal of Experimental Medicine · doi:10.1084/jem.20031074 · Cited by 1,101
Self-citationDavis, R. E., Brown, K. D., Siebenlist, U., & Staudt, L. M. (2001) · The Journal of Experimental Medicine · doi:10.1084/jem.194.12.1861 · Cited by 1,051
Self-citationWright, G., Tan, B., Rosenwald, A., Hurt, E. H., Wiestner, A., & Staudt, L. M. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1732008100 · Cited by 1,040
Self-citationMutations of multiple genes cause deregulation of NF-κB in diffuse large B-cell lymphoma
Compagno, M., Lim, W. K., Grunn, A., Nandula, S. V., Brahmachary, M., Shen, Q., Bertoni, F., Ponzoni, M., Scandurra, M., Califano, A., et al. (2009) · Nature · doi:10.1038/nature07968 · Cited by 1,038
Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways
Lenz, G., Wright, G. W., Emre, N. C. T., Kohlhammer, H., Dave, S. S., Davis, R. E., Carty, S., Lam, L. T., Shaffer, A. L., Xiao, W., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0804295105 · Cited by 995
Self-citationJohnson, N. A., Slack, G. W., Savage, K. J., Connors, J. M., Ben-Neriah, S., Rogic, S., Scott, D. W., Tan, K. L., Steidl, C., Sehn, L. H., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.41.0985 · Cited by 975
Self-citationLohr, J. G., Stojanov, P., Lawrence, M. S., Auclair, D., Chapuy, B., Sougnez, C., Cruz-Gordillo, P., Knoechel, B., Asmann, Y. W., Slager, S. L., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1121343109 · Cited by 974
Analysis of the coding genome of diffuse large B-cell lymphoma
Pasqualucci, L., Trifonov, V., Fabbri, G., Ma, J., Rossi, D., Chiarenza, A., Wells, V. A., Grunn, A., Messina, M., Elliot, O., et al. (2011) · Nature Genetics · doi:10.1038/ng.892 · Cited by 971
Wilson, W. H., O'Connor, O. A., Czuczman, M. S., LaCasce, A. S., Gerecitano, J. F., Leonard, J. P., Tulpule, A., Dunleavy, K., Xiong, H., Chiu, Y.-L., et al. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70261-8 · Cited by 876
Self-citationOncogenic CARD11 Mutations in Human Diffuse Large B Cell Lymphoma
Lenz, G., Davis, R. E., Ngo, V. N., Lam, L., George, T. C., Wright, G. W., Dave, S. S., Zhao, H., Xu, W., Rosenwald, A., et al. (2008) · Science · doi:10.1126/science.1153629 · Cited by 867
Self-citationBéguelin, W., Popovic, R., Teater, M., Jiang, Y., Bunting, K. L., Rosen, M., Shen, H., Yang, S. N., Wang, L., Ezponda, T., et al. (2013) · Cancer Cell · doi:10.1016/j.ccr.2013.04.011 · Cited by 846
Chen, B. J., Chapuy, B., Ouyang, J., Sun, H. H., Roemer, M. G. M., Xu, M. L., Yu, H., Fletcher, C. D. M., Freeman, G. J., Shipp, M. A., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0855 · Cited by 843
Pfreundschuh, M., Kuhnt, E., Trümper, L., Österborg, A., Trneny, M., Shepherd, L., Gill, D. S., Walewski, J., Pettengell, R., Jaeger, U., et al. (2011) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70235-2 · Cited by 792
A selective inhibitor of EZH2 blocks H3K27 methylation and kills mutant lymphoma cells
Knutson, S. K., Wigle, T. J., Warholic, N. M., Sneeringer, C. J., Allain, C. J., Klaus, C. R., Sacks, J. D., Raimondi, A., Majer, C. R., Song, J., et al. (2012) · Nature Chemical Biology · doi:10.1038/nchembio.1084 · Cited by 776
Development of PI3K inhibitors: lessons learned from early clinical trials
Rodon, J., Dienstmann, R., Serra, V., & Tabernero, J. (2013) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2013.10 · Cited by 766
Lannutti, B. J., Meadows, S. A., Herman, S. E. M., Kashishian, A., Steiner, B., Johnson, A. J., Byrd, J. C., Tyner, J. W., Loriaux, M. M., Deininger, M., et al. (2011) · Blood · doi:10.1182/blood-2010-03-275305 · Cited by 720
Green, T. M., Young, K. H., Visco, C., Xu-Monette, Z. Y., Orazi, A., Go, R. S., Nielsen, O., Gadeberg, O. V., Mourits-Andersen, T., Frederiksen, M., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.41.4342 · Cited by 686
Sneeringer, C. J., Scott, M. P., Kuntz, K. W., Knutson, S. K., Pollock, R. M., Richon, V. M., & Copeland, R. A. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1012525107 · Cited by 683
Berger, R., Rotem-Yehudar, R., Slama, G., Landes, S., Kneller, A., Leiba, M., Koren-Michowitz, M., Shimoni, A., & Nagler, A. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-4079 · Cited by 680
The BCL6 proto-oncogene suppresses p53 expression in germinal-centre B cells
Phan, R. T., & Dalla-Favera, R. (2004) · Nature · doi:10.1038/nature03147 · Cited by 679
Hu, S., Xu-Monette, Z. Y., Tzankov, A., Green, T., Wu, L., Balasubramanyam, A., Liu, W.-M., Visco, C., Li, Y., Miranda, R. N., et al. (2013) · Blood · doi:10.1182/blood-2012-10-460063 · Cited by 679
Aukema, S. M., Siebert, R., Schuuring, E., van Imhoff, G. W., Kluin-Nelemans, H. C., Boerma, E.-J., & Kluin, P. M. (2011) · Blood · doi:10.1182/blood-2010-09-297879 · Cited by 678
PI3 Kinase Signals BCR-Dependent Mature B Cell Survival
Srinivasan, L., Sasaki, Y., Calado, D. P., Zhang, B., Paik, J. H., DePinho, R. A., Kutok, J. L., Kearney, J. F., Otipoby, K. L., & Rajewsky, K. (2009) · Cell · doi:10.1016/j.cell.2009.08.041 · Cited by 661
Savage, K. J., Johnson, N. A., Ben-Neriah, S., Connors, J. M., Sehn, L. H., Farinha, P., Horsman, D. E., & Gascoyne, R. D. (2009) · Blood · doi:10.1182/blood-2009-05-220095 · Cited by 660
MHC class II transactivator CIITA is a recurrent gene fusion partner in lymphoid cancers
Steidl, C., Shah, S. P., Woolcock, B. W., Rui, L., Kawahara, M., Farinha, P., Johnson, N. A., Zhao, Y., Telenius, A., Neriah, S. B., et al. (2011) · Nature · doi:10.1038/nature09754 · Cited by 615
Self-citationYap, D. B., Chu, J., Berg, T., Schapira, M., Cheng, S.-W. G., Moradian, A., Morin, R. D., Mungall, A. J., Meissner, B., Boyle, M., et al. (2011) · Blood · doi:10.1182/blood-2010-11-321208 · Cited by 606
Lymphomas with concurrent BCL2 and MYC translocations: the critical factors associated with survival
Johnson, N. A., Savage, K. J., Ludkovski, O., Ben-Neriah, S., Woods, R., Steidl, C., Dyer, M. J. S., Siebert, R., Kuruvilla, J., Klasa, R., et al. (2009) · Blood · doi:10.1182/blood-2009-03-212191 · Cited by 587
Dose-Adjusted EPOCH-Rituximab Therapy in Primary Mediastinal B-Cell Lymphoma
Dunleavy, K., Pittaluga, S., Maeda, L. S., Advani, R., Chen, C. C., Hessler, J., Steinberg, S. M., Grant, C., Wright, G., Varma, G., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1214561 · Cited by 569
Self-citationCunningham, D., Hawkes, E. A., Jack, A., Qian, W., Smith, P., Mouncey, P., Pocock, C., Ardeshna, K. M., Radford, J. A., McMillan, A., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(13)60313-x · Cited by 561
Frequent inactivation of A20 in B-cell lymphomas
Kato, M., Sanada, M., Kato, I., Sato, Y., Takita, J., Takeuchi, K., Niwa, A., Chen, Y., Nakazaki, K., Nomoto, J., et al. (2009) · Nature · doi:10.1038/nature07969 · Cited by 555
Selective inhibition of Ezh2 by a small molecule inhibitor blocks tumor cells proliferation
Qi, W., Chan, H., Teng, L., Li, L., Chuai, S., Zhang, R., Zeng, J., Li, M., Fan, H., Lin, Y., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1210371110 · Cited by 547
Horn, H., Ziepert, M., Becher, C., Barth, T. F. E., Bernd, H.-W., Feller, A. C., Klapper, W., Hummel, M., Stein, H., Hansmann, M.-L., et al. (2013) · Blood · doi:10.1182/blood-2012-06-435842 · Cited by 542
B cell antigen receptor signaling 101
DALPORTO, J. (2004) · Molecular Immunology · doi:10.1016/j.molimm.2004.04.008 · Cited by 537
Lenz, G., & Staudt, L. M. (2010) · New England Journal of Medicine · doi:10.1056/nejmra0807082 · Cited by 528
Self-citationGenetic heterogeneity of diffuse large B-cell lymphoma
Zhang, J., Grubor, V., Love, C. L., Banerjee, A., Richards, K. L., Mieczkowski, P. A., Dunphy, C., Choi, W., Au, W. Y., Srivastava, G., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1205299110 · Cited by 527
Exploiting Synthetic Lethality for the Therapy of ABC Diffuse Large B Cell Lymphoma
Yang, Y., Shaffer, A. L., Emre, N. C. T., Ceribelli, M., Zhang, M., Wright, G., Xiao, W., Powell, J., Platig, J., Kohlhammer, H., et al. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.05.024 · Cited by 521
Self-citationDunleavy, K., Pittaluga, S., Czuczman, M. S., Dave, S. S., Wright, G., Grant, N., Shovlin, M., Jaffe, E. S., Janik, J. E., Staudt, L. M., et al. (2009) · Blood · doi:10.1182/blood-2009-01-199679 · Cited by 497
Self-citationRelapsed/Refractory Diffuse Large B-Cell Lymphoma
Friedberg, J. W. (2011) · Hematology · doi:10.1182/asheducation-2011.1.498 · Cited by 497
Silencing of human polycomb target genes is associated with methylation of histone H3 Lys 27
Kirmizis, A., Bartley, S. M., Kuzmichev, A., Margueron, R., Reinberg, D., Green, R., & Farnham, P. J. (2004) · Genes & Development · doi:10.1101/gad.1200204 · Cited by 495
ADVANCED DIFFUSE HISTIOCYTIC LYMPHOMA, A POTENTIALLY CURABLE DISEASE
Devita, V., Canellos, G., Chabner, B., Schein, P., Hubbard, S., & Young, R. (1975) · The Lancet · doi:10.1016/s0140-6736(75)91142-3 · Cited by 484
Medicine, N. L. O. (2008) · Journal of Pain & Palliative Care Pharmacotherapy · doi:10.1080/15360280801989377 · Cited by 468
Targeting pathological B cell receptor signalling in lymphoid malignancies
Young, R. M., & Staudt, L. M. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd3937 · Cited by 401
Self-citationRécher, C., Coiffier, B., Haioun, C., Molina, T. J., Fermé, C., Casasnovas, O., Thiéblemont, C., Bosly, A., Laurent, G., Morschhauser, F., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(11)61040-4 · Cited by 355
Lam, L. T., Wright, G., Davis, R. E., Lenz, G., Farinha, P., Dang, L., Chan, J. W., Rosenwald, A., Gascoyne, R. D., & Staudt, L. M. (2008) · Blood · doi:10.1182/blood-2007-09-111948 · Cited by 353
Self-citationIntegration of B cell responses through Toll-like receptors and antigen receptors
Rawlings, D. J., Schwartz, M. A., Jackson, S. W., & Meyer-Bahlburg, A. (2012) · Nature Reviews Immunology · doi:10.1038/nri3190 · Cited by 339
Fu, K., Weisenburger, D. D., Choi, W. W. L., Perry, K. D., Smith, L. M., Shi, X., Hans, C. P., Greiner, T. C., Bierman, P. J., Bociek, R. G., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.9277 · Cited by 334
Ruan, J., Martin, P., Furman, R. R., Lee, S. M., Cheung, K., Vose, J. M., LaCasce, A., Morrison, J., Elstrom, R., Ely, S., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.31.1142 · Cited by 319
Lam, L. T., Davis, R. E., Pierce, J., Hepperle, M. E., Xu, Y., Foley, M. H., Nong, Y., Wen, D., Adams, J., Dang, L., et al. (2005) · PubMed · Cited by 312
Self-citationHernandez‐Ilizaliturri, F. J., Deeb, G., Zinzani, P. L., Pileri, S. A., Malik, F., Macon, W. R., Goy, A., Witzig, T. E., & Czuczman, M. S. (2011) · Cancer · doi:10.1002/cncr.26135 · Cited by 304
Basso, K., & Dalla-Favera, R. (2010) · Advances in Immunology · doi:10.1016/s0065-2776(10)05007-8 · Cited by 302
Velichutina, I., Shaknovich, R., Geng, H., Johnson, N. A., Gascoyne, R. D., Melnick, A. M., & Elemento, O. (2010) · Blood · doi:10.1182/blood-2010-04-280149 · Cited by 299
Ding, B. B., Yu, J. J., Yu, R. Y.-L., Mendez, L. M., Shaknovich, R., Zhang, Y., Cattoretti, G., & Ye, B. H. (2008) · Blood · doi:10.1182/blood-2007-04-087734 · Cited by 298
A phase II trial of the oral mTOR inhibitor everolimus in relapsed aggressive lymphoma
Witzig, T. E., Reeder, C. B., LaPlant, B. R., Gupta, M., Johnston, P. B., Micallef, I. N., Porrata, L. F., Ansell, S. M., Colgan, J. P., Jacobsen, E. D., et al. (2011) · Leukemia · doi:10.1038/leu.2010.226 · Cited by 297
A Small-Molecule Inhibitor of BCL6 Kills DLBCL Cells In Vitro and In Vivo
Cerchietti, L. C., Ghetu, A. F., Zhu, X., Da Silva, G. F., Zhong, S., Matthews, M., Bunting, K. L., Polo, J. M., Farès, C., Arrowsmith, C. H., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2009.12.050 · Cited by 288
Cooperative Epigenetic Modulation by Cancer Amplicon Genes
Rui, L., Emre, N. C. T., Kruhlak, M. J., Chung, H.-J., Steidl, C., Slack, G., Wright, G. W., Lenz, G., Ngo, V. N., Shaffer, A. L., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.11.013 · Cited by 283
Self-citationIqbal, J., Sanger, W. G., Horsman, D. E., Rosenwald, A., Pickering, D. L., Dave, B., Dave, S., Xiao, L., Cao, K., Zhu, Q., et al. (2004) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)63284-1 · Cited by 279
Self-citationThieblemont, C., Briere, J., Mounier, N., Voelker, H.-U., Cuccuini, W., Hirchaud, E., Rosenwald, A., Jack, A., Sundstrom, C., Cogliatti, S., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.35.4423 · Cited by 275
Pfeifer, M., Grau, M., Lenze, D., Wenzel, S.-S., Wolf, A., Wollert-Wulf, B., Dietze, K., Nogai, H., Storek, B., Madle, H., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1305656110 · Cited by 270
MALT1 Small Molecule Inhibitors Specifically Suppress ABC-DLBCL In Vitro and In Vivo
Fontan, L., Yang, C., Kabaleeswaran, V., Volpon, L., Osborne, M. J., Beltran, E., Garcia, M., Cerchietti, L., Shaknovich, R., Yang, S. N., et al. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.11.003 · Cited by 264
CERVICAL CARCINOMA IN YOUNGER PATIENTS
Bouma, J., & Crane-Elders, A. B. F. (1983) · The Lancet · doi:10.1016/s0140-6736(83)92628-4 · Cited by 263
B Cell Antigen Receptor Signaling: Roles in Cell Development and Disease
Gauld, S. B., Dal Porto, J. M., & Cambier, J. C. (2002) · Science · doi:10.1126/science.1071546 · Cited by 261
Ruxolitinib: The First FDA Approved Therapy for the Treatment of Myelofibrosis
Mascarenhas, J., & Hoffman, R. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-3145 · Cited by 250
Saijo, K., Mecklenbräuker, I., Santana, A., Leitger, M., Schmedt, C., & Tarakhovsky, A. (2002) · The Journal of Experimental Medicine · doi:10.1084/jem.20020408 · Cited by 244
Feuerhake, F. (2005) · Blood · doi:10.1182/blood-2004-12-4901 · Cited by 244
Nagel, D., Spranger, S., Vincendeau, M., Grau, M., Raffegerst, S., Kloo, B., Hlahla, D., Neuenschwander, M., Peter von Kries, J., Hadian, K., et al. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.11.002 · Cited by 233
Robertson, M. J., Kahl, B. S., Vose, J. M., de Vos, S., Laughlin, M., Flynn, P. J., Rowland, K., Cruz, J. C., Goldberg, S. L., Musib, L., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.3146 · Cited by 232
Prostate Stem Cell Antigen Is Overexpressed in Prostate Cancer Metastases
Lam, J. S., Yamashiro, J., Shintaku, I. P., Vessella, R. L., Jenkins, R. B., Horvath, S., Said, J. W., & Reiter, R. E. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-1842 · Cited by 211
The molecular pathogenesis of primary mediastinal large B-cell lymphoma
Steidl, C., & Gascoyne, R. D. (2011) · Blood · doi:10.1182/blood-2011-05-326538 · Cited by 206
Essential role of MALT1 protease activity in activated B cell-like diffuse large B-cell lymphoma
Hailfinger, S., Lenz, G., Ngo, V., Posvitz-Fejfar, A., Rebeaud, F., Guzzardi, M., Penas, E.-M. M., Dierlamm, J., Chan, W. C., Staudt, L. M., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0907511106 · Cited by 204
Self-citationFerch, U., Kloo, B., Gewies, A., Pfänder, V., Düwel, M., Peschel, C., Krappmann, D., & Ruland, J. (2009) · Journal of Experimental Medicine · doi:10.1084/jem.20091167 · Cited by 203
Smith, S. M., van Besien, K., Karrison, T., Dancey, J., McLaughlin, P., Younes, A., Smith, S., Stiff, P., Lester, E., Modi, S., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.29.2813 · Cited by 202
Constitutive STAT6 activation in primary mediastinal large B-cell lymphoma
Guiter, C., Dusanter-Fourt, I., Copie-Bergman, C., Boulland, M.-L., le Gouvello, S., Gaulard, P., Leroy, K., & Castellano, F. (2004) · Blood · doi:10.1182/blood-2003-10-3545 · Cited by 197
The CARMA1 signalosome links the signalling machinery of adaptive and innate immunity in lymphocytes
Rawlings, D. J., Sommer, K., & Moreno-García, M. E. (2006) · Nature Reviews Immunology · doi:10.1038/nri1944 · Cited by 190
A peptomimetic inhibitor of BCL6 with potent antilymphoma effects in vitro and in vivo
Cerchietti, L. C., Yang, S. N., Shaknovich, R., Hatzi, K., Polo, J. M., Chadburn, A., Dowdy, S. F., & Melnick, A. (2009) · Blood · doi:10.1182/blood-2008-07-168773 · Cited by 183
BCL2 mutations in diffuse large B-cell lymphoma
Schuetz, J. M., Johnson, N. A., Morin, R. D., Scott, D. W., Tan, K. X., Neriah, S. B., Boyle, M., Slack, G. W., Marra, M. A., Connors, J. M., et al. (2011) · Leukemia · doi:10.1038/leu.2011.378 · Cited by 171
Wilson, W. H., Gerecitano, J. F., Goy, A., de Vos, S., Kenkre, V. P., Barr, P. M., Blum, K. A., Shustov, A. R., Advani, R. H., Lih, J., et al. (2012) · Blood · doi:10.1182/blood.v120.21.686.686 · Cited by 170
Self-citationZhang, L., Kosek, J., Wang, M., Heise, C., Schafer, P. H., & Chopra, R. (2013) · British Journal of Haematology · doi:10.1111/bjh.12172 · Cited by 167
Wilson, W. H., Jung, S.-H., Porcu, P., Hurd, D., Johnson, J., Martin, S. E., Czuczman, M., Lai, R., Said, J., Chadburn, A., et al. (2012) · Haematologica · doi:10.3324/haematol.2011.056531 · Cited by 167
Self-citationPathogenetic importance and therapeutic implications of NF‐κB in lymphoid malignancies
Lim, K., Yang, Y., & Staudt, L. M. (2012) · Immunological Reviews · doi:10.1111/j.1600-065x.2012.01105.x · Cited by 157
Self-citationEberle, F. C., Rodriguez‐Canales, J., Wei, L., Hanson, J. C., Killian, J. K., Sun, H., Adams, L. G., Hewitt, S. M., Wilson, W. H., Pittaluga, S., et al. (2011) · Haematologica · doi:10.3324/haematol.2010.033167 · Cited by 146
Self-citationDavids, M. S., Deng, J., Wiestner, A. U., Lannutti, B. J., Wang, L., Wu, C. J., Wilson, W. H., Brown, J. R., & Letai, A. G. (2012) · Blood · doi:10.1182/blood-2012-02-414060 · Cited by 144
Self-citationYounes, A., Romaguera, J. E., Fanale, M. A., McLaughlin, P. J., Hagemeister, F. B., Copeland, A. R. M., Neelapu, S. S., Kwak, L. W., Shah, J. J., Faria, S. D. C., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.42.5223 · Cited by 143
Malignant pirates of the immune system
Rui, L., Schmitz, R., Ceribelli, M., & Staudt, L. M. (2011) · Nature Immunology · doi:10.1038/ni.2094 · Cited by 140
Self-citationNF-κB/STAT3/PI3K signaling crosstalk in iMycEμ B lymphoma
Han, S., Yun, H., Son, D.-J., Tompkins, V. S., Peng, L., Chung, S.-T., Kim, J., Park, E.-S., & Janz, S. (2010) · Molecular Cancer · doi:10.1186/1476-4598-9-97 · Cited by 128
Furman, R. R., Byrd, J. C., Brown, J. R., Coutre, S. E., Benson, D. M., Wagner‐Johnston, N. D., Flinn, I. W., Kahl, B. S., Spurgeon, S. E. F., Lannutti, B. J., et al. (2010) · Blood · doi:10.1182/blood.v116.21.55.55 · Cited by 123
Tristetraprolin Impairs Myc-Induced Lymphoma and Abolishes the Malignant State
Rounbehler, R. J., Fallahi, M., Yang, C., Steeves, M. A., Li, W., Doherty, J. R., Schaub, F. X., Sanduja, S., Dixon, D. A., Blackshear, P. J., et al. (2012) · Cell · doi:10.1016/j.cell.2012.06.033 · Cited by 122
STAT3 Inhibition Is a Therapeutic Strategy for ABC-like Diffuse Large B-Cell Lymphoma
Scuto, A., Kujawski, M., Kowolik, C. M., Krymskaya, L., Wang, L., Weiss, L. M., DiGiusto, D. L., Yu, H., Forman, S. J., & Jove, R. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-2380 · Cited by 121
Naylor, T. L., Tang, H., Ratsch, B. A., Enns, A., Loo, A. T., Chen, L., Lenz, P., Waters, N. J., Schüler, W., Dörken, B., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-2525 · Cited by 119
Strauss, S. J., Higginbottom, K., Jueliger, S., Maharaj, L., Allen, P. D., Schenkein, D. P., Lister, T. A., & Joel, S. P. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-3254 · Cited by 111
Shortt, J., Martin, B. P., Newbold, A., Hannan, K. M., Devlin, J. R., Baker, A. J., Ralli, R., Cullinane, C. M., Schmitt, C. A., Reimann, M., et al. (2013) · Blood · doi:10.1182/blood-2012-08-446096 · Cited by 74
Petrich, A. M., Leshchenko, V. V., Kuo, P.-Y., Xia, B., Thirukonda, V. K., Ulahannan, N., Gordon, S. A. K., Fazzari, M. J., Ye, B. H., Sparano, J. A., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-1407 · Cited by 65
My Treatment Approach to Patients With Diffuse Large B-Cell Lymphoma
Armitage, J. O. (2012) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2011.11.007 · Cited by 64
Grant, C. M., Dunleavy, K. M., Eberle, F. C., Pittaluga, S., Wilson, W. H., & Jaffe, E. S. (2011) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-011-0090-1 · Cited by 59
Self-citationPAK1 Mediates Resistance to PI3K Inhibition in Lymphomas
Walsh, K. J., McKinney, M. S., Love, C., Liu, Q., Fan, A., Patel, A., Smith, J., Beaven, A., Jima, D. D., & Davé, S. S. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-1060 · Cited by 52
MALT1 Protease: A New Therapeutic Target in B Lymphoma and Beyond?
McAllister‐Lucas, L. M., Baens, M., & Lucas, P. C. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-0467 · Cited by 47
Gu, J. J., Hernandez‐Ilizaliturri, F. J., Kaufman, G. P., Czuczman, N. M., Mavis, C. K., Skitzki, J. J., & Czuczman, M. S. (2013) · British Journal of Haematology · doi:10.1111/bjh.12452 · Cited by 42
PCI-32765: a novel Bruton's tyrosine kinase inhibitor for the treatment of lymphoid malignancies
Winer, E. S., Ingham, R. R., & Castillo, J. J. (2012) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2012.656199 · Cited by 42
Lenalidomide – Current Understanding of Mechanistic Properties
Tageja, N. (2011) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/187152011795347487 · Cited by 40
Kim, S. W., Oleksyn, D. W., Rossi, R. M., Jordan, C. T., Sanz, I., Chen, L., & Zhao, J. (2007) · Blood · doi:10.1182/blood-2007-05-088591 · Cited by 36
IRAK4 Kinase As A Novel Therapeutic Target in the ABC Subtype of Diffuse Large B Cell Lymphoma
Lim, K.-H., Romero, D. L., Chaudhary, D., Robinson, S. D., & Staudt, L. M. (2012) · Blood · doi:10.1182/blood.v120.21.62.62 · Cited by 21
Self-citationSteinhardt, J. J., & Gartenhaus, R. B. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-0217 · Cited by 12
Cited by
The 2016 revision of the World Health Organization classification of lymphoid neoplasms
Swerdlow, S. H., Campo, E., Pileri, S. A., Harris, N. L., Stein, H., Siebert, R., Advani, R., Ghielmini, M., Salles, G. A., Zelenetz, A. D., et al. (2016) · Blood · doi:10.1182/blood-2016-01-643569 · Cited by 7,831
“Although the clinical implications of these mutations are not fully understood, there are increasing expectations that they will become important in guiding future targeted therapies.(62,72)”
Role of Bruton’s tyrosine kinase in B cells and malignancies
Pal Singh, S., Dammeijer, F., & Hendriks, R. W. (2018) · Molecular Cancer · doi:10.1186/s12943-018-0779-z · Cited by 726
Sehn, L. H., & Gascoyne, R. D. (2015) · Blood · doi:10.1182/blood-2014-05-577189 · Cited by 560
Scott, D. W., Mottok, A., Ennishi, D., Wright, G. W., Farinha, P., Ben-Neriah, S., Kridel, R., Barry, G. S., Hother, C., Abrisqueta, P., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.60.2383 · Cited by 405
Self-citationGenetics of diffuse large B-cell lymphoma
Pasqualucci, L., & Dalla-Favera, R. (2018) · Blood · doi:10.1182/blood-2017-11-764332 · Cited by 282
Metadata
- Authors
- Roschewski, M., Staudt, L. M., & Wilson, W. H.
- Venue
- Nature Reviews Clinical Oncology
- Published
- 2013-11-12
- Volume
- 11
- Issue
- 1
- Pages
- 12-23
- ISSN
- 1759-4774 (ISSN-L)
- 1759-4782
- OpenAlex
- W2044306036
- Cited by
- 411
- References
- 129
- FWCI
- 4.70
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.